Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2018-03-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
第七届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jinling Pharmaceutical Co., Ltd. It details the meeting held on March 23, 2018, including the approval of various reports such as the 2017 Supervisory Board Work Report, 2017 Financial Final Report, 2017 Profit Distribution Plan, Internal Control Self-Evaluation Report, and the 2017 Annual Report and its summary. The document also mentions that the 2017 Annual Report was reviewed and approved by the Supervisory Board, confirming its compliance with laws and regulations. However, the document itself is not the full Annual Report but a meeting resolution announcing the approval of these reports and related decisions. The length is short (1886 characters), and it serves as an official announcement of the Supervisory Board's resolutions rather than the full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than the full Annual Report (10-K) or Management Report (MDA).
2018-03-26 Chinese
2017年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2017 Annual Report" of Jinling Pharmaceutical Company Limited, covering the full year 2017 (January 1 to December 31). It includes detailed sections such as company overview, financial data, business analysis, management discussion and analysis, and governance information. The content contains comprehensive financial figures, business operations, risk factors, and management commentary typical of a full annual report. The document length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2017
2018-03-26 Chinese
2017年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2017 Annual Report Summary" of Jinling Pharmaceutical Co., Ltd. It contains detailed financial data for the year 2017, including revenue, net profit, earnings per share, and other financial indicators. It also discusses the company's business operations, management strategies, industry environment, and accounting policy changes. The length of the document (13,189 characters) and the presence of comprehensive financial and operational information indicate this is a full annual report rather than a brief announcement or summary. The document is not a mere announcement of report availability but contains substantive financial data and analysis. Therefore, it fits the definition of an Annual Report (10-K). FY 2017
2018-03-26 Chinese
独立董事2017年度述职报告（王广基）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2017 Annual Report" and contains a detailed account of the independent director's activities, attendance at board meetings, opinions expressed, committee work, and efforts to protect shareholder rights during the year 2017. It is a narrative report on the director's duties and performance rather than a financial report or announcement. It does not contain financial statements or data, nor is it an announcement of voting results or management changes. This fits best under Board/Management Information (MANG), as it relates to the role and activities of a board member.
2018-03-26 Chinese
2017年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year ending December 31, 2017, issued by Jinling Pharmaceutical Co., Ltd. It discusses the evaluation of the company's internal control effectiveness, including financial and non-financial internal control defects, their classification, and remediation status. The content is detailed and specific to internal control evaluation rather than a full annual report or audit report. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a brief announcement or certification but a substantive report on internal control evaluation. This matches the description of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, including internal control evaluation results. Therefore, the document should be classified as AR with high confidence. FY 2017
2018-03-26 Chinese
2017年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report for the fiscal year 2017 of Jinling Pharmaceutical Co., Ltd. It contains detailed auditor opinions, audit basis, key audit matters, management responsibilities, and extensive financial statement notes. The content includes audit opinions on the 2017 financial statements, detailed accounting policies, and notes on financial items such as receivables, inventory, and investments. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It is clearly an audit report, not an annual report or other filing type, as it focuses on the auditor's opinion and audit procedures rather than the full company annual report. Therefore, the correct classification is Audit Report / Information (AR). FY 2017
2018-03-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.